...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Therapeutic advances in endocrinology and metabolism. >Conversion from insulin glargine U-100 to insulin glargine U-300 or insulin degludec and the impact on dosage requirements
【24h】

Conversion from insulin glargine U-100 to insulin glargine U-300 or insulin degludec and the impact on dosage requirements

机译：从甘精胰岛素U-100转化为甘精胰岛素U-300或胰岛素地格曲克及其对剂量要求的影响

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

We wanted to determine whether basal insulin requirements change when patients transition from insulin glargine U-100 (Gla-100) to insulin glargine U-300 (Gla-300) or insulin degludec. This study involved subjects seen in the University of Colorado Health Endocrine Clinic who were transitioned from Gla-100 to either Gla-300 (n = 95) or insulin degludec (n = 39). The primary outcome was the difference between baseline Gla-100 dose and dose of Gla-300 or insulin degludec prescribed after first follow-up visit within 1–12 months. Secondary outcomes included changes in glycemic control and empiric dose conversion from Gla-100 to Gla-300 or insulin degludec on the day of transition. Wilcoxon rank sum tests evaluated changes in insulin doses, and paired t tests assessed changes in glycemic control using GraphPad statistical software. Median daily basal insulin dose increased for individuals transitioned from Gla-100 to Gla-300 from 30 [19–60 interquartile range (IQR)] units at baseline to 34.5 (19–70 IQR) units after follow up (p = 0.01). For patients transitioned to insulin degludec, dose changes from baseline to follow up were not significantly different (p = 0.56). At the time of transition, the prescribed dose of Gla-300 or insulin degludec did not significantly differ from the previous dose of Gla-100 (p = 0.73 and 0.28, respectively), indicating that empiric dose adjustments were not routinely prescribed. Patients who transitioned from Gla-100 to Gla-300 had increased basal insulin requirements between visits, while basal insulin requirements for those transitioned from Gla-100 to insulin degludec were not significantly different.
机译：我们想确定当患者从甘精胰岛素U-100（Gla-100）转变为甘精胰岛素U-300（Gla-300）或脱地胰岛素时基础胰岛素需求是否发生变化。这项研究涉及在科罗拉多大学健康内分泌诊所中看到的受试者，他们从Gla-100转变为Gla-300（n = 95）或胰岛素地高卢德（n = 39）。主要结局是基线Gla-100剂量与在1-12个月内首次随访后开具的Gla-300剂量或胰岛素地格曲克剂量之间的差异。次要结果包括在过渡日血糖控制的变化以及从Gla-100到Gla-300的经验剂量转换或胰岛素地格雷德。 Wilcoxon秩和检验使用GraphPad统计软件评估了胰岛素剂量的变化，配对的t检验评估了血糖控制的变化。从Gla-100过渡到Gla-300的个体的每日基础胰岛素中位数从基线的30 [19-60四分位间距（IQR）]单位增加到随访后的34.5（19-70 IQR）单位（p = 0.01）。对于过渡至胰岛素地德戈的患者，从基线到随访的剂量变化无明显差异（p = 0.56）。在过渡时，Gla-300或脱地格胰岛素的处方剂量与之前的Gla-100剂量（分别分别为p = 0.73和0.28）没有显着差异，表明经验性剂量调整未常规进行。从Gla-100转变为Gla-300的患者在两次就诊之间的基础胰岛素需求量增加，而从Gla-100转变为地戈德胰岛素的患者的基础胰岛素需求量没有显着差异。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号